Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia
October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia. REXULTI works on three neurotransmitter systems: serotonin, dopamine and noradrenaline.1
The efficacy and safety of REXULTI have been demonstrated in two short-term studies and one long-term maintenance trial.1
REXULTI tablets are taken once daily and come in dose strengths of 1 mg, 2 mg, 3 mg and 4 mg with a recommended target dose of 2-4 mg/day.
Lundbeck Australia and Otsuka Australia Pharmaceutical are dedicated to bringing innovative new medicines to Australians with psychiatric disorders.
Please review the REXULTI Approved Product Information before prescribing. Product information is available by calling Lundbeck on 1300 721 277 or click here.
Hand Sanitisers in healthcare: a hygienic retrospect for a healthy future
Looking back four years, the COVID-19 pandemic caught us unexpectedly and triggered a global...
Stay a Step Ahead of Hidden Threats of Winter Infections
As the winter season looms, healthcare facilities brace themselves for heightened challenges in...
How a Pharmaceutical Giant Ensures the Safety and Authenticity of Medicines Through Serialisation
In an era where pharmaceutical traceability is paramount, Aspen Australia, a subsidiary of Aspen...
